DashboardAll companies
Run this on your own research
Common Stock · Common Stock

EyesVision Corporation

031310KRX₩900−₩10 (−1.10%)Market closed

Price Chart

Daily

Key facts

Market Cap
₩26.77B
P/E
2.4x
P/B
0.14x
ROE
6.3%

EyesVision Corporation

Common Stock · Common Stock · FY 2025

EyesVision Corporation is a prominent player in the healthcare sector, specifically focusing on the development and manufacturing of advanced ophthalmic products. The company's primary function is to innovate and deliver cutting-edge solutions for eye care, including diagnostic technologies and therapeutic treatments. EyesVision's products cater to a broad range of eye conditions, impacting both preventative care and advanced medical interventions. The corporation works closely with ophthalmologists, clinics, and healthcare facilities to ensure that their offerings meet the evolving needs of the industry and adhere to rigorous regulatory standards. A key characteristic of EyesVision is its commitment to research and development, which positions it at the forefront of new technologies and treatment methodologies that enhance visual health. In the financial market, EyesVision Corporation plays a crucial role by contributing to the healthcare and life sciences sectors, and its initiatives often influence trends in medical technology and patient care. Through its innovative approach, EyesVision supports the global endeavor to improve eye health and access to quality ophthalmic care.

CEO
김상우, 안필성
Employees
0

Company Statistics

Valuation

P/E
2.4x
P/B
0.14x
P/S
0.12x
EV/EBITDA
6.4x
P/FCF
3.0x

Margins

Gross
21.7%
EBITDA
5.7%
Operating
1.7%
Pre-Tax
4.6%
Net
4.5%

Returns

ROA
3.4%
ROE
6.3%
ROIC
4.5%

Growth (CAGR)

Rev 3Yr
0.5%
Rev 5Yr
7.5%
Op Inc 3Yr
−17.9%
Net Inc 3Yr
—

Financial Health

Cash & Cash Equivalents
₩37.98B
Net Debt
₩40.88B
Debt/Equity
38.4%
Interest Cov
—

Profile

Revenue
₩194.38B
Shares Out
29.7M
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
EyesVision Corporation (031310) Stock Forecast 2026 ₩900 — Price, Financials & Analyst Targets | AlphaLenz